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Opinion
Mitochondrial replacement to prevent
the transmission of mitochondrial
DNA disease
Mary Herbert1 & Doug Turnbull2
M itochondrial medicine has seenmajor advances over recent years.The development of new genetic
technology has enabled the genetic diagnosis
to be established in an increasing number of
patients. This has led to a recognition that
mitochondrial diseases are not rare, but one
of the most common group of genetic
diseases. Associated with these advances,
there have been undoubted improvements
in the care of patients with mitochondrial
disease. This is particularly true in the UK
where the development of an NHS Highly
Specialised service for patients with mito-
chondrial disease has enabled access of all
mitochondrial patients to advanced diagnos-
tic services, and to clinics which enable the
multidisciplinary care for both children and
adults.
Whilst all in the field would acknowledge
the major achievements over the last few
years, sadly the other advances have not
been mirrored by advances in curative treat-
ments [1]. Whilst supportive care can make
a major difference to a patient’s life expec-
tancy and quality of life, these remain
progressive conditions, which lead to signifi-
cant morbidity and mortality. In our focus
groups with mitochondrial patients, whilst
they greatly appreciate all the current efforts,
for the vast majority of families with mito-
chondrial disease, the most important issue
is how they can have healthy offspring. For
families with nuclear genetic defects, the
options are no different from other nuclear
defects, but for women with mitochondrial
DNA (mtDNA) disorders, the choices are
considerably more challenging [2]. It is upon
this background we have to place the
discussion about the ethics and feasibility of
preventing the transmission of mitochondrial
DNA disease by nuclear transfer techniques.
MtDNA is purely maternally inherited
and since it is present in multiple copies,
patients can either have all mutated mtDNA
(homoplasmic mutations) or a mixture of
mutated and wild-type mtDNA (hetero-
plasmic mutations). Women with mtDNA
mutations already have a number of different
options available. These range from not
considering having any children through to
preimplantation genetic diagnosis (PGD)—a
technique which is very appropriate for some
women with some heteroplasmic mtDNA
defects [3]. However, for women with either
homoplasmic mtDNA mutations or with high
levels of heteroplasmy, PGD is not an option.
Thus, the approach of transferring nuclear
DNA from an oocyte or zygote into a donor-
enucleated oocyte or zygote to prevent the
transmission of mtDNA disease is now a
potentially viable option for mothers.
Despite the recent surge in interest in
these approaches, it may come as a
surprise that some of the proposed IVF
techniques have been around since the
early 1980s. The pioneering work of
McGrath and Solter established that it is
feasible to transfer the nuclear DNA (as
pronuclei) between mouse zygotes [4] and
that the offspring generated this way are
healthy. The technique of pronuclear trans-
fer has thus been used successfully in many
different rodent laboratories for over
30 years. More recently, other options such
as metaphase II spindle transfer [5] and
polar body transfer [6] have been shown to
be effective in either rodent or primate
models. All methods of nuclear transfer
have shown that the carryover of mtDNA
between oocytes or zygotes is very low and
well below the threshold of disease. Thus,
in theory, it would be possible to prevent
the transmission of mtDNA disease.
As with any scientific advance, it is never
that easy. For mitochondrial replacement,
there are four big challenges: ethics, legality,
safety and efficacy. The ethical issues
around this work are considerable and often
polarise to either very opposed or very posi-
tive for the technique. These issues have
been considered in great detail by the
Nuffield Council on Bioethics (http://
nuffieldbioethics.org/project/mitochondrial-
dna-disorders/), but it is important to recog-
nise that one’s own ethical stance may influ-
ence the assessment of the whole technique.
The legality and regulation of the technique
will vary markedly between countries. In
the UK, there is a highly regulated environ-
ment for IVF techniques and there has been
very detailed consideration of the proposals
to prevent transmission of mtDNA muta-
tions including an extensive public enquiry
which was broadly supportive of the tech-
nique. Following debates in which both
Houses of Parliament voted overwhelmingly
for a change to UK legislation, Regulations
were passed to enable the Human Fertilisa-
tion and Embryology Authority (HFEA) to
consider applications to use pronuclear
transfer and spindle transfer in clinical treat-
ment to prevent transmission of mtDNA
disease. These Regulations will come into
force in October 2015. Once the HFEA’s
requirements are known, clinics in the UK
can then apply for a licence.
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For patients, and the doctors looking after
them, perhaps the biggest concern is the
safety of these techniques and also how likely
a woman is to become pregnant after the
mitochondrial replacement. Both these issues
have been extensively considered (studying
both published and unpublished work) on
three separate occasions by a panel of inde-
pendent experts (including developmental
biologists, IVF experts and clinical geneti-
cists). On every occasion (including as
recently as March 2014, http://www.hfea.
gov.uk/8807.html), these independent
experts have found no substantial reason to
believe that these techniques would not be
safe. They have suggested some further
experiments to be completed before they
think treatment licences should be consid-
ered, and they could see no reason why the
legislation in the UK should not go forward.
It is rare that any new technique has
undergone such extensive public and
scientific debate, and of course, there will
always be those opposed to such advances
on either ethical or scientific grounds.
However, we believe it is really important to
remember why these techniques are being
proposed and that ultimately we do hope
that women with mtDNA disease will be
able to make reproductive choices that
include the possibility that their own
offspring is free from disease.
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